CoChat

MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Open access
Maddipati, Ravikanth, Norgard, Robert J., Baslan, Timour, Rathi, Komal S., Zhang, Amy, Saeid, Asal, Higashihara, Taku, Wu, Feng, Kumar, Angad, Annamalai, Valli, Bhattacharya, Saurav, Raman, Pichai, Adkisson, Christian A., Pitarresi, Jason R., Wengyn, Maximilian D., Yamazoe, Taiji, Li, Jinyang, Balli, David, LaRiviere, Michael J., Ngo, Tuong-Vi C., Folkert, Ian W., Millstein, Ian D., Bermeo, Jonathan, Carpenter, Erica L., McAuliffe, John C., Oktay, Maja H., Brekken, Rolf A., Lowe, Scott W., Iacobuzio-Donahue, Christine A., Notta, Faiyaz, Stanger, Ben Z. · 2022 · Cancer Discovery
Cited by 97

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

The degree of metastatic disease varies widely among patients with cancer and affects clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multifluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC)—a tumor type in which most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of MYC and its downstream targets. Functional experiments showed that MYC promotes metastasis by recruiting tumor-associated macrophages, leading to greater bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically in metastatic patients. Collectively, these results implicate MYC activity as a major determinant of metastatic burden in advanced PDAC. Significance: Here, we investigate metastatic variation seen clinically in patients with PDAC and murine PDAC tumors and identify MYC as a major driver of this heterogeneity. This article is highlighted in the In This Issue feature, p. 275

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-1826

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 97

Metadata

Authors
Maddipati, R., Norgard, R. J., Baslan, T., Rathi, K. S., Zhang, A., Saeid, A., Higashihara, T., Wu, F., Kumar, A., Annamalai, V., Bhattacharya, S., Raman, P., Adkisson, C. A., Pitarresi, J. R., Wengyn, M. D., Yamazoe, T., Li, J., Balli, D., LaRiviere, M. J., Ngo, T.-V. C., Folkert, I. W., Millstein, I. D., Bermeo, J., Carpenter, E. L., McAuliffe, J. C., Oktay, M. H., Brekken, R. A., Lowe, S. W., Iacobuzio-Donahue, C. A., Notta, F., & Stanger, B. Z.
Venue
Cancer Discovery
Published
2021-09-22
Volume
12
Issue
2
Pages
542-561
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3199556667
Cited by
97
References
28
FWCI
4.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-1826
The paper
Maddipati, R., Norgard, R. J., Baslan, T., Rathi, K. S., Zhang, A., Saeid, A., Higashihara, T., Wu, F., Kumar, A., Annamalai, V., Bhattacharya, S., Raman, P., Adkisson, C. A., Pitarresi, J. R., Wengyn, M. D., Yamazoe, T., Li, J., Balli, D., LaRiviere, M. J., . . . Stanger, B. Z. (2022). MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-1826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.